Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
Apellis Pharmaceuticals (Nasdaq: APLS) has announced it will host a conference call and webcast on November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apellis Pharmaceuticals (Nasdaq: APLS) has announced it will host a conference call and webcast on November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results. Interested parties can pre-register for the call, and a live audio webcast with accompanying slides will be accessible through the company's website. A replay of the webcast will be available for 90 days following the event.
Apellis is a global biopharmaceutical company focused on developing life-changing therapies for challenging diseases. They have introduced the first new class of complement medicine in 15 years and currently have two approved medicines targeting C3, including the first-ever therapy for geographic atrophy, a leading cause of blindness worldwide. The company aims to further explore the potential of targeting C3 across various retinal, rare, and neurological diseases.
Positive
- Apellis has two approved medicines targeting C3
- Developed first-ever therapy for geographic atrophy, a leading cause of blindness
Negative
- None.
Details
News Market Reaction – APLS
The recorded move for APLS in the trading session of this news was +2.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2024 financial results on Tuesday, November 5, 2024, at 8:30 a.m. ET.
To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.